AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) is a designer drug that acts as a potent and selective agonist for the cannabinoid receptor CB<sub>1</sub>. It is used in scientific research for mapping the distribution of CB<sub>1</sub> receptors.
AM-694 is an agonist for cannabinoid receptors. It has a K<sub>i</sub> of 0.08 nM at CB<sub>1</sub> and 18 times selectivity over CB<sub>2</sub> with a K<sub>i</sub> of 1.44 nM. It is unclear what is responsible for this unusually high CB<sub>1</sub> binding affinity, but it makes the <sup>18</sup>F radiolabelled derivative of AM-694 useful for mapping the distribution of CB<sub>1</sub> receptors in the body.
Pathways of metabolism include hydrolytic defluorination, carboxylation, and monohydroxylation of the N-alkyl chain.
AM-694 is scheduled in the "government decree on psychoactive substances banned from the consumer market".